TOP TIERMARKET NEWSWIRE

News & sentiment

AARDVARK THERAPEUTIC (AARD) — News & AI sentiment

AARDVARK THERAPEUTIC (AARD) news roundup. 21 stories in the past week, 71 over 30 days. Average 30-day sentiment is 40.9/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $395K — net selling of $395K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

21

avg sentiment 48.3/100

30d stories

71

avg sentiment 40.9/100

Insider net (90d)

$395K

0 buys · 1 sells

Congress (90d)

0

0 buys · 0 sells

AARD news in the last 24 hours, 7 days, 30 days and 90 days

How much AARD coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	AARD stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	21	48.3/100	AARD headlines →
Last 30 days	71	40.9/100	AARD headlines →
Last 90 days	163	41/100	AARD headlines →

Latest stories on AARD

Aardvark Therapeutics price target lowered to $10 from $19 at Jones

The Fly34 · bearishanalyst

2d ago

Aardvark Therapeutics stock rating cut to Perform by Oppenheimer

Investing.com Analyst Ratings34 · bearishanalyst

3d ago

Aardvark Therapeutics downgraded to Perform from Outperform at Oppenheimer

The Fly34 · bearishanalyst

3d ago

Important Notice Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); Power Solutions International, Inc. (NASDAQ: PSIX); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire34 · bearishgeneral

3d ago

H.C. Wainwright cuts Aardvark Therapeutics stock price target to $2

Investing.com Analyst Ratings34 · bearishanalyst

3d ago

Aardvark Therapeutics price target lowered to $2 from $4 at H.C. Wainwright

The Fly34 · bearishanalyst

3d ago

Aardvark Therapeutics price target lowered to $1.50 from $4 at BofA

The Fly34 · bearishanalyst

3d ago

Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript

Seeking Alpha34 · bearishearnings

6d ago

Aardvark Therapeutics price target lowered to $2.50 from $6 at RBC Capital

The Fly34 · bearishanalyst

6d ago

Aardvark Therapeutics, Inc. (AARD) files 8-K

SEC 8-K50 · neutralgeneral

6d ago

Aardvark Therapeutics reports exploratory efficacy data from HERO trial

The Fly63 · neutralproduct/pr

6d ago

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

GlobeNewswire38 · neutralproduct/pr

6d ago

Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials

Business Insider38 · neutralearnings

6d ago

FDA Lifts Aardvark Therapeutics Clinical Hold, Shares Rise

Morningstar74 · bullishproduct/pr

7d ago

Aardvark Therapeutics stock surges as FDA lifts clinical hold

Investing.com Markets74 · bullishproduct/pr

7d ago

Aardvark Therapeutics Inc trading resumes

The Fly50 · neutralgeneral

7d ago

FDA lifts hold on Aardvark Therapeutics IND application for ARD-101

The Fly74 · bullishproduct/pr

7d ago

Aardvark Therapeutics: FDA Lifts ARD-101 Clinical Halt

MarketWatch74 · bullishproduct/pr

7d ago

Aardvark Therapeutics, Inc. (AARD) files 8-K

SEC 8-K50 · neutralgeneral

7d ago

Aardvark Therapeutics Inc trading halted, news pending

The Fly50 · neutralgeneral

7d ago

Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data

GlobeNewswire74 · bullishproduct/pr

7d ago

Aardvark Therapeutics rises as a shareholder investigation spotlights ARD-101 safety claims and trial setbacks October 21, 2026

MarketChameleon34 · bearishgeneral

Oct 21

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire34 · bearishgeneral

Oct 21

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Bank of America Corporation (NYSE: BAC); Coastal Financial Corporation (NASDAQ: CCB); and Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is Investigating Claims on Your Behalf

GlobeNewswire34 · bearishgeneral

Oct 20

H.C. Wainwright cuts Aardvark Therapeutics price target on trial termination

Investing.com Analyst Ratings31 · bearishanalyst

Oct 19

Open AARD in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →